Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

The risk of cardiovascular disease in prostate cancer patients receiving androgen deprivation therapies.

Cardwell CR, O'Sullivan JM, Jain S, Harbinson MT, Cook MB, Hicks BM, Mc Menamin ÚC.

Epidemiology. 2019 Oct 21. doi: 10.1097/EDE.0000000000001132. [Epub ahead of print]

PMID:
31651660
2.

Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.

Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, Polard E, Nowak E, Oger E.

Eur J Cancer. 2017 May;77:99-108. doi: 10.1016/j.ejca.2017.03.002. Epub 2017 Apr 5.

PMID:
28390298
3.

Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.

Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.

Eur Urol. 2019 Apr;75(4):676-683. doi: 10.1016/j.eururo.2018.11.022. Epub 2018 Nov 26.

PMID:
30497883
4.

Dose-dependent effect of androgen deprivation therapy for localized prostate cancer on adverse cardiac events.

Schmid M, Sammon JD, Reznor G, Kapoor V, Speed JM, Abdollah FA, Sood A, Chun FK, Kibel AS, Menon M, Fisch M, Sun M, Trinh QD.

BJU Int. 2016 Aug;118(2):221-9. doi: 10.1111/bju.13203. Epub 2015 Jul 22.

5.

Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care.

Martín-Merino E, Johansson S, Morris T, García Rodríguez LA.

Drug Saf. 2011 Nov 1;34(11):1061-77. doi: 10.2165/11594540-000000000-00000.

PMID:
21981434
6.

[Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].

Merseburger AS, Sedding D, Hüter K.

Urologe A. 2016 Feb;55(2):218-25. doi: 10.1007/s00120-015-0013-1. Review. German.

PMID:
26637324
7.

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.

Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5. Review.

8.

Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

Azoulay L, Yin H, Benayoun S, Renoux C, Boivin JF, Suissa S.

Eur Urol. 2011 Dec;60(6):1244-50. doi: 10.1016/j.eururo.2011.08.041. Epub 2011 Aug 27.

PMID:
21908097
9.

Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy.

O'Farrell S, Sandström K, Garmo H, Stattin P, Holmberg L, Adolfsson J, Van Hemelrijck M.

BJU Int. 2016 Sep;118(3):391-8. doi: 10.1111/bju.13360. Epub 2015 Nov 19.

11.

Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.

Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, Xiang S, Wang S.

Prostate Cancer Prostatic Dis. 2018 Nov;21(4):451-460. doi: 10.1038/s41391-018-0059-4. Epub 2018 Jul 9.

PMID:
29988099
12.

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.

PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.

13.

Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.

Klil-Drori AJ, Yin H, Tagalakis V, Aprikian A, Azoulay L.

Eur Urol. 2016 Jul;70(1):56-61. doi: 10.1016/j.eururo.2015.06.022. Epub 2015 Jun 29.

PMID:
26138040
14.

Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.

Greiman AK, Keane TE.

Curr Urol Rep. 2017 Jun;18(6):41. doi: 10.1007/s11934-017-0688-5. Review.

PMID:
28417429
15.

Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.

Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI.

Eur Urol. 2014 Dec;66(6):1125-32. doi: 10.1016/j.eururo.2014.01.026. Epub 2014 Jan 28.

PMID:
24495466
16.

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.

Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, Briganti A, Montorsi F, Karakiewicz PI.

BJU Int. 2014 Dec;114(6b):E82-E89. doi: 10.1111/bju.12732. Epub 2014 Jul 27.

17.

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer.

Keating NL, O'Malley AJ, Freedland SJ, Smith MR.

J Natl Cancer Inst. 2010 Jan 6;102(1):39-46. doi: 10.1093/jnci/djp404. Epub 2009 Dec 7. Erratum in: J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23.

18.

Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.

Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.

BJU Int. 2012 Dec;110(11):1721-8. doi: 10.1111/j.1464-410X.2012.11107.x. Epub 2012 Apr 13.

19.

Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer.

Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S.

JAMA. 2013 Jul 17;310(3):289-96. doi: 10.1001/jama.2013.8638.

PMID:
23860987
20.

Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.

Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, Holmberg L, Adolfsson J, Van Hemelrijck M.

Int J Cancer. 2016 Dec 15;139(12):2698-2704. doi: 10.1002/ijc.30403. Epub 2016 Sep 19.

Supplemental Content

Support Center